Cargando…

Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry

BACKGROUND: Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans (‘triptan resistance’) could be considered eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruscheweyh, Ruth, Gossrau, Gudrun, Dresler, Thomas, Freilinger, Tobias, Förderreuther, Stefanie, Gaul, Charly, Kraya, Torsten, Neeb, Lars, Ruschil, Victoria, Straube, Andreas, Scheidt, Jörg, Jürgens, Tim Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563311/
https://www.ncbi.nlm.nih.gov/pubmed/37817093
http://dx.doi.org/10.1186/s10194-023-01676-0
_version_ 1785118312711061504
author Ruscheweyh, Ruth
Gossrau, Gudrun
Dresler, Thomas
Freilinger, Tobias
Förderreuther, Stefanie
Gaul, Charly
Kraya, Torsten
Neeb, Lars
Ruschil, Victoria
Straube, Andreas
Scheidt, Jörg
Jürgens, Tim Patrick
author_facet Ruscheweyh, Ruth
Gossrau, Gudrun
Dresler, Thomas
Freilinger, Tobias
Förderreuther, Stefanie
Gaul, Charly
Kraya, Torsten
Neeb, Lars
Ruschil, Victoria
Straube, Andreas
Scheidt, Jörg
Jürgens, Tim Patrick
author_sort Ruscheweyh, Ruth
collection PubMed
description BACKGROUND: Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans (‘triptan resistance’) could be considered eligible for treatment with the novel medications from the ditan and gepant groups. There is little data on the frequency of ‘triptan resistance’. METHODS: We used patient self-report data from the German Migraine and Headache Society (DMKG) Headache Registry to assess triptan response and triptan efficacy and/or tolerability failure. RESULTS: A total of 2284 adult migraine patients (females: 85.4%, age: 39.4 ± 12.8 years) were included. 42.5% (n = 970) had failed ≥ 1 triptan, 13.1% (n = 300) had failed ≥ 2 triptans (meeting the EHF definition of ‘triptan resistance’), and 3.9% (n = 88) had failed ≥ 3 triptans. Compared to triptan responders (current use, no failure, n = 597), triptan non-responders had significantly more severe migraine (higher frequency (p < 0.001), intensity (p < 0.05), and disability (p < 0.001)), that further increased with the level of triptan failure. Responders rates were highest for nasal and oral zolmitriptan, oral eletriptan and subcutaneous sumatriptan. CONCLUSION: In the present setting (specialized headache care in Germany), 13.1% of the patients had failed ≥ 2 triptans. Triptan failure was associated with increased migraine severity and disability, emphasizing the importance of establishing an effective and tolerable acute migraine medication. Acute treatment optimization might include switching to one of the triptans with the highest responder rates and/or to a different acute medication class. TRIAL REGISTRATION: The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10194-023-01676-0.
format Online
Article
Text
id pubmed-10563311
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-105633112023-10-11 Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry Ruscheweyh, Ruth Gossrau, Gudrun Dresler, Thomas Freilinger, Tobias Förderreuther, Stefanie Gaul, Charly Kraya, Torsten Neeb, Lars Ruschil, Victoria Straube, Andreas Scheidt, Jörg Jürgens, Tim Patrick J Headache Pain Research BACKGROUND: Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans (‘triptan resistance’) could be considered eligible for treatment with the novel medications from the ditan and gepant groups. There is little data on the frequency of ‘triptan resistance’. METHODS: We used patient self-report data from the German Migraine and Headache Society (DMKG) Headache Registry to assess triptan response and triptan efficacy and/or tolerability failure. RESULTS: A total of 2284 adult migraine patients (females: 85.4%, age: 39.4 ± 12.8 years) were included. 42.5% (n = 970) had failed ≥ 1 triptan, 13.1% (n = 300) had failed ≥ 2 triptans (meeting the EHF definition of ‘triptan resistance’), and 3.9% (n = 88) had failed ≥ 3 triptans. Compared to triptan responders (current use, no failure, n = 597), triptan non-responders had significantly more severe migraine (higher frequency (p < 0.001), intensity (p < 0.05), and disability (p < 0.001)), that further increased with the level of triptan failure. Responders rates were highest for nasal and oral zolmitriptan, oral eletriptan and subcutaneous sumatriptan. CONCLUSION: In the present setting (specialized headache care in Germany), 13.1% of the patients had failed ≥ 2 triptans. Triptan failure was associated with increased migraine severity and disability, emphasizing the importance of establishing an effective and tolerable acute migraine medication. Acute treatment optimization might include switching to one of the triptans with the highest responder rates and/or to a different acute medication class. TRIAL REGISTRATION: The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10194-023-01676-0. Springer Milan 2023-10-10 /pmc/articles/PMC10563311/ /pubmed/37817093 http://dx.doi.org/10.1186/s10194-023-01676-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ruscheweyh, Ruth
Gossrau, Gudrun
Dresler, Thomas
Freilinger, Tobias
Förderreuther, Stefanie
Gaul, Charly
Kraya, Torsten
Neeb, Lars
Ruschil, Victoria
Straube, Andreas
Scheidt, Jörg
Jürgens, Tim Patrick
Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry
title Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry
title_full Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry
title_fullStr Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry
title_full_unstemmed Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry
title_short Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry
title_sort triptan non-response in specialized headache care: cross-sectional data from the dmkg headache registry
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563311/
https://www.ncbi.nlm.nih.gov/pubmed/37817093
http://dx.doi.org/10.1186/s10194-023-01676-0
work_keys_str_mv AT ruscheweyhruth triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT gossraugudrun triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT dreslerthomas triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT freilingertobias triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT forderreutherstefanie triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT gaulcharly triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT krayatorsten triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT neeblars triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT ruschilvictoria triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT straubeandreas triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT scheidtjorg triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry
AT jurgenstimpatrick triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry